BR0306732A - Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico - Google Patents
Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgicoInfo
- Publication number
- BR0306732A BR0306732A BR0306732-7A BR0306732A BR0306732A BR 0306732 A BR0306732 A BR 0306732A BR 0306732 A BR0306732 A BR 0306732A BR 0306732 A BR0306732 A BR 0306732A
- Authority
- BR
- Brazil
- Prior art keywords
- ige antibody
- allergic disease
- combination treatments
- administering
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000026935 allergic disease Diseases 0.000 title abstract 2
- 230000003266 anti-allergic effect Effects 0.000 title abstract 2
- 238000011284 combination treatment Methods 0.000 title abstract 2
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 239000000168 bronchodilator agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 210000003630 histaminocyte Anatomy 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002617 leukotrienes Chemical class 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 abstract 1
- 229960005330 pimecrolimus Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"TRATAMENTOS EM COMBINAçãO PARA DOENçA ALéRGICA COMPREENDENDO A ADMINISTRAçãO DE UM ANTI-CORPO ANTI-IGE E COMPOSTO ANTIALéRGICO". A presente invenção refere-se a composição farmacêutica que compreende um anticorpo anti-IgE e pelo menos um outro composto antialérgico selecionado dentre o grupo consistindo em agentes antiinflamatórios, modificadores de leucotrieno, broncodilatadores, anti-histaminas, antagonistas de interleucina, inibidores de mastócitos, e agentes imunoterapêuticos, como 33-epicloro,33-desoxiascomicina (pimecrolimus), em que os ingredientes ativos estão presentes na forma livre ou na forma de um sal farmaceuticamente aceitável ou opcionalmente pelo menos um veículo farmaceuticamente aceitável para uso simultâneo, separado ou seq³encial.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0200429.9A GB0200429D0 (en) | 2002-01-09 | 2002-01-09 | Organic compounds |
| PCT/EP2003/000154 WO2003057249A1 (en) | 2002-01-09 | 2003-01-09 | Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0306732A true BR0306732A (pt) | 2004-12-28 |
Family
ID=9928810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0306732-7A BR0306732A (pt) | 2002-01-09 | 2003-01-09 | Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050042215A1 (pt) |
| EP (1) | EP1465662A1 (pt) |
| JP (1) | JP2005514414A (pt) |
| CN (1) | CN1612751A (pt) |
| AU (1) | AU2003210153A1 (pt) |
| BR (1) | BR0306732A (pt) |
| CA (1) | CA2472151A1 (pt) |
| GB (1) | GB0200429D0 (pt) |
| WO (1) | WO2003057249A1 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005512946A (ja) * | 2001-05-09 | 2005-05-12 | ノバルティス アクチエンゲゼルシャフト | 選択的免疫調節法 |
| GB0307867D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| US20090263381A1 (en) * | 2003-07-31 | 2009-10-22 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| JP2007505932A (ja) * | 2003-09-18 | 2007-03-15 | マクサイト， インコーポレイテッド | 経強膜送達 |
| US20060263350A1 (en) * | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| WO2005030331A1 (en) * | 2003-09-26 | 2005-04-07 | Fairfield Clinical Trials, Llc | Combination antihistamine medication |
| GB0502358D0 (en) * | 2005-02-04 | 2005-03-16 | Novartis Ag | Organic compounds |
| WO2006086750A1 (en) * | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Liquid formulations for treatment of diseases or conditions |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| US8492400B2 (en) | 2006-02-09 | 2013-07-23 | Santen Pharmaceutical Co., Ltd. | Stable formulations, and methods of their preparation and use |
| CN101443004B (zh) * | 2006-03-23 | 2013-03-06 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂 |
| EP2592094A1 (en) * | 2007-02-15 | 2013-05-15 | AstraZeneca AB | Binding members for IgE molecules |
| US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
| JP7169985B2 (ja) * | 2017-11-07 | 2022-11-11 | ヒュービットジェノミクス株式会社 | ＩｇＥクラスに特異的な免疫反応の抑制効果を介した乳児期のアレルギー素因獲得を阻止する方法 |
| JP7589045B2 (ja) * | 2018-03-26 | 2024-11-25 | ノバルティス アーゲー | リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法 |
| CN114504644B (zh) * | 2021-12-24 | 2024-02-13 | 北京大学第一医院 | 抗IgE抗体在用于治疗腺样体肥大中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| AU766492B2 (en) * | 1998-09-18 | 2003-10-16 | Dynavax Technologies Corporation | Methods of treating IgE-associated disorders and compositions for use therein |
| GB0012383D0 (en) * | 2000-05-22 | 2000-07-12 | Novartis Ag | Organic compounds |
-
2002
- 2002-01-09 GB GBGB0200429.9A patent/GB0200429D0/en not_active Ceased
-
2003
- 2003-01-09 EP EP03729238A patent/EP1465662A1/en not_active Withdrawn
- 2003-01-09 CA CA002472151A patent/CA2472151A1/en not_active Abandoned
- 2003-01-09 CN CNA03802053XA patent/CN1612751A/zh active Pending
- 2003-01-09 AU AU2003210153A patent/AU2003210153A1/en not_active Abandoned
- 2003-01-09 WO PCT/EP2003/000154 patent/WO2003057249A1/en not_active Ceased
- 2003-01-09 BR BR0306732-7A patent/BR0306732A/pt not_active IP Right Cessation
- 2003-01-09 US US10/500,200 patent/US20050042215A1/en not_active Abandoned
- 2003-01-09 JP JP2003557606A patent/JP2005514414A/ja active Pending
-
2006
- 2006-06-19 US US11/455,431 patent/US20060240000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050042215A1 (en) | 2005-02-24 |
| CN1612751A (zh) | 2005-05-04 |
| JP2005514414A (ja) | 2005-05-19 |
| US20060240000A1 (en) | 2006-10-26 |
| WO2003057249A1 (en) | 2003-07-17 |
| GB0200429D0 (en) | 2002-02-27 |
| EP1465662A1 (en) | 2004-10-13 |
| CA2472151A1 (en) | 2003-07-17 |
| AU2003210153A1 (en) | 2003-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005070126A3 (en) | Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors | |
| BR0209689A (pt) | Uso de fragmento de hmg como agente anti-inflamatório | |
| BRPI0411241A (pt) | agentes terapêuticos úteis para o tratamento de dor | |
| BR0317524A (pt) | Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso | |
| AR085778A2 (es) | Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato | |
| DE60021570D1 (de) | Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor | |
| BR0316305A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit | |
| AR003468A1 (es) | Uso de un compuesto para la manufactura de medicamentos utiles para el tratamiento del asma alergico | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| AR038927A1 (es) | Sales de acido organico | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| AR033688A1 (es) | Composicion parenteral reconstituible | |
| TR199802769T2 (xx) | Terpenoid bileşikler ile antihistaminik bileşiklerin bir kombinasyonunu ihtiva eden topikal bileşim. | |
| WO2005107801A3 (en) | Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| BR0014946A (pt) | Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina | |
| BRPI0607349A2 (pt) | combinação de xolair com agente imunossupressor | |
| BR0113148A (pt) | Composições de 2-piridinamina e métodos relacionados | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| ATE390124T1 (de) | Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin | |
| RU2006143689A (ru) | Эпитопы, индуцирующие гибель т-клеток | |
| BRPI0515555A (pt) | composição farmacêutica compreendendo éster de temozolomida | |
| SE0000303D0 (sv) | Novel compounds | |
| JP2001518516A5 (pt) | ||
| BR0212077A (pt) | Compostos de aminopirróis como agentes antiinflamatórios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |